{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:09:02Z","timestamp":1794355742582,"version":"4.9.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Challenges in the precise diagnosis and treatment of nasopharyngeal carcinoma (NPC) remain, mainly due to the absence of a multi-omics-based molecular classification and effective targeted therapies. In this study, we performed proteomic and phosphoproteomic analyses of NPC and non-cancerous nasopharyngeal tissues to identify key dysregulated proteins and phosphorylation networks. Based on these profiles, we classified NPC into two distinct molecular subtypes: S1 and S2, which exhibit significant clinical heterogeneity. Notably, the S2 subtype displayed stronger immune suppressive characteristics. By leveraging proteomic data from both cancerous and non-cancerous tissues, as well as from the two molecular subtypes, we developed robust diagnostic and prognostic models. Through computational drug repurposing and experimental validation, we identified Panobinostat, a pan-histone deacetylase inhibitor, as a potent anti-tumor agent for NPC, demonstrating efficacy in both in vitro and in vivo models. Mechanistically, Panobinostat inhibits MYC expression, thereby suppressing the transcriptional activation of key components in the homologous recombination (HR) DNA repair pathway. This reduction in transcriptional activation impairs HR repair efficiency and leads to the accumulation of DNA double-strand breaks (DSBs). Furthermore, combination therapy with Panobinostat and radiotherapy produced a synergistic effect, significantly enhancing NPC suppression. Additionally, we predicted and validated potential drugs for targeting the S2 subtype of NPC. In conclusion, we identified molecular subtypes of NPC, constructed preliminary diagnostic and prognostic marker panels, and observed the therapeutic potential of Panobinostat, as a monotherapy and in combination with radiotherapy. These findings provide a solid foundation for precision diagnosis, prognostic stratification, and personalized treatment strategies for NPC.<\/jats:p>","DOI":"10.1038\/s41392-026-02742-0","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:01:55Z","timestamp":1782169315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Large-scale and high-resolution mass spectrometry-based proteomics defines molecular subtypes of nasopharyngeal carcinoma for therapeutic targeting"],"prefix":"10.1038","volume":"11","author":[{"given":"Yi-Ping","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-8924","authenticated-orcid":false,"given":"Yao-Hui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ying","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-4162","authenticated-orcid":false,"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4391-8706","authenticated-orcid":false,"given":"Qin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2742_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64\u201380 (2019).","journal-title":"Lancet"},{"key":"2742_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1079515","volume":"13","author":"W Li","year":"2022","unstructured":"Li, W. et al. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. Front Immunol. 13, 1079515 (2022).","journal-title":"Front Immunol."},{"key":"2742_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong, K. C. W. et al. Nasopharyngeal carcinoma: An evolving paradigm. Nat. Rev. Clin. Oncol. 18, 679\u2013695 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2742_CR4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","volume":"387","author":"MLK Chua","year":"2016","unstructured":"Chua, M. L. K., Wee, J. T. S., Hui, E. P. & Chan, A. T. C. Nasopharyngeal carcinoma. Lancet 387, 1012\u20131024 (2016).","journal-title":"Lancet"},{"key":"2742_CR5","first-page":"e4210","volume":"11","author":"AA Almobarak","year":"2019","unstructured":"Almobarak, A. A., Jebreel, A. B. & Abu-Zaid, A. Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma: A comprehensive literature review. Cureus 11, e4210 (2019).","journal-title":"Cureus"},{"key":"2742_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24348-6","volume":"12","author":"JP Bruce","year":"2021","unstructured":"Bruce, J. P. et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-\u03baB activation and immune escape. Nat. Commun. 12, 4193 (2021).","journal-title":"Nat. Commun."},{"key":"2742_CR7","doi-asserted-by":"publisher","first-page":"11283","DOI":"10.1073\/pnas.1607606113","volume":"113","author":"H Zheng","year":"2016","unstructured":"Zheng, H. et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-\u03baB pathway regulators in nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA 113, 11283\u201311288 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2742_CR8","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/carcin\/bgy108","volume":"39","author":"C Tu","year":"2018","unstructured":"Tu, C. et al. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing. Carcinogenesis 39, 1517\u20131528 (2018).","journal-title":"Carcinogenesis"},{"key":"2742_CR9","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.3390\/curroncol29090475","volume":"29","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Nasopharyngeal carcinoma progression: Accumulating genomic instability and persistent Epstein-Barr virus infection. Curr. Oncol. 29, 6035\u20136052 (2022).","journal-title":"Curr. Oncol."},{"key":"2742_CR10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","volume":"51","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat. Genet 51, 1131\u20131136 (2019).","journal-title":"Nat. Genet"},{"key":"2742_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/msb.2010.59","volume":"6","author":"C Vogel","year":"2010","unstructured":"Vogel, C. et al. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol. Syst. Biol. 6, 400 (2010).","journal-title":"Mol. Syst. Biol."},{"key":"2742_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/mas.20356","volume":"31","author":"HT Tan","year":"2012","unstructured":"Tan, H. T., Lee, Y. H. & Chung, M. C. Cancer proteomics. Mass Spectrom. Rev. 31, 583\u2013605 (2012).","journal-title":"Mass Spectrom. Rev."},{"key":"2742_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2020.05.043","volume":"182","author":"JY Xu","year":"2020","unstructured":"Xu, J. Y. et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 182, 245\u2013261.e217 (2020).","journal-title":"Cell"},{"key":"2742_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25202-5","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. Nat. Commun. 12, 4961 (2021).","journal-title":"Nat. Commun."},{"key":"2742_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28524-0","volume":"13","author":"K Asleh","year":"2022","unstructured":"Asleh, K. et al. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat. Commun. 13, 896 (2022).","journal-title":"Nat. Commun."},{"key":"2742_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41586-019-1173-8","volume":"569","author":"MA Eckert","year":"2019","unstructured":"Eckert, M. A. et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature 569, 723\u2013728 (2019).","journal-title":"Nature"},{"key":"2742_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccell.2018.12.003","volume":"35","author":"DG Mun","year":"2019","unstructured":"Mun, D. G. et al. Proteogenomic characterization of human early-onset gastric cancer. Cancer Cell 35, 111\u2013124.e110 (2019).","journal-title":"Cancer Cell"},{"key":"2742_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","volume":"179","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 179, 561\u2013577.e522 (2019).","journal-title":"Cell"},{"key":"2742_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s43018-022-00479-7","volume":"4","author":"DY Hyeon","year":"2023","unstructured":"Hyeon, D. Y. et al. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Nat. Cancer 4, 290\u2013307 (2023).","journal-title":"Nat. Cancer"},{"key":"2742_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100567","volume":"22","author":"Y Fu","year":"2023","unstructured":"Fu, Y. et al. Proteomics profiling reveals the molecular signatures and potential therapeutic targets of human nasopharyngeal carcinoma. Mol. Cell Proteom. 22, 100567 (2023).","journal-title":"Mol. Cell Proteom."},{"key":"2742_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jprot.2014.06.025","volume":"109","author":"J Yang","year":"2014","unstructured":"Yang, J. et al. Identification of candidate biomarkers for the early detection of nasopharyngeal carcinoma by quantitative proteomic analysis. J. Proteom. 109, 162\u2013175 (2014).","journal-title":"J. Proteom."},{"key":"2742_CR22","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.mam.2022.101097","volume":"86","author":"S Pan","year":"2022","unstructured":"Pan, S. & Chen, R. Pathological implication of protein post-translational modifications in cancer. Mol. Asp. Med. 86, 101097 (2022).","journal-title":"Mol. Asp. Med."},{"key":"2742_CR23","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1038\/sj.onc.1203525","volume":"19","author":"CV Ramana","year":"2000","unstructured":"Ramana, C. V., Chatterjee-Kishore, M., Nguyen, H. & Stark, G. R. Complex roles of Stat1 in regulating gene expression. Oncogene 19, 2619\u20132627 (2000).","journal-title":"Oncogene"},{"key":"2742_CR24","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1164\/ajrccm\/152.4_Pt_2.S67","volume":"152","author":"MA Horisberger","year":"1995","unstructured":"Horisberger, M. A. Interferons, Mx genes, and resistance to influenza virus. Am. J. Respir. Crit. Care Med. 152, S67\u2013S71 (1995).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2742_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli, A. et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272\u2013280 (2014).","journal-title":"Autoimmun. Rev."},{"key":"2742_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7150\/ijbs.5613","volume":"9","author":"X Zhou","year":"2013","unstructured":"Zhou, X. et al. Interferon induced IFIT family genes in host antiviral defense. Int J. Biol. Sci. 9, 200\u2013208 (2013).","journal-title":"Int J. Biol. Sci."},{"key":"2742_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cell.2010.09.033","volume":"143","author":"B Skaug","year":"2010","unstructured":"Skaug, B. & Chen, Z. J. Emerging role of ISG15 in antiviral immunity. Cell 143, 187\u2013190 (2010).","journal-title":"Cell"},{"key":"2742_CR28","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.immuni.2014.05.007","volume":"40","author":"J Zhu","year":"2014","unstructured":"Zhu, J. et al. Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity 40, 936\u2013948 (2014).","journal-title":"Immunity"},{"key":"2742_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0163-7258(91)90005-7","volume":"52","author":"LM Pfeffer","year":"1991","unstructured":"Pfeffer, L. M. & Colamonici, O. R. Transmembrane signalling by interferon-alpha. Pharm. Ther. 52, 149\u2013157 (1991).","journal-title":"Pharm. Ther."},{"key":"2742_CR30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41422-020-00402-8","volume":"30","author":"S Jin","year":"2020","unstructured":"Jin, S. et al. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Res 30, 950\u2013965 (2020).","journal-title":"Cell Res"},{"key":"2742_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0964-1955(93)90036-E","volume":"29b","author":"U H\u00f8rding","year":"1993","unstructured":"H\u00f8rding, U., Nielsen, H. W., Albeck, H. & Daugaard, S. Nasopharyngeal carcinoma: histopathological types and association with Epstein-Barr Virus. Eur. J. Cancer B Oral. Oncol. 29b, 137\u2013139 (1993).","journal-title":"Eur. J. Cancer B Oral. Oncol."},{"key":"2742_CR32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/0008-5472.CAN-06-1882","volume":"67","author":"DM Pegtel","year":"2007","unstructured":"Pegtel, D. M. et al. IFN-alpha-stimulated genes and Epstein-Barr virus gene expression distinguish WHO type II and III nasopharyngeal carcinomas. Cancer Res 67, 474\u2013481 (2007).","journal-title":"Cancer Res"},{"key":"2742_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1667\/RR3039","volume":"160","author":"K Kita","year":"2003","unstructured":"Kita, K. et al. Involvement of LEU13 in interferon-induced refractoriness of human RSa cells to cell killing by X rays. Radiat. Res 160, 302\u2013308 (2003).","journal-title":"Radiat. Res"},{"key":"2742_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/biom11050622","volume":"11","author":"M Padariya","year":"2021","unstructured":"Padariya, M. et al. Functional interfaces, biological pathways, and regulations of interferon-related DNA damage resistance signature (IRDS) genes. Biomolecules 11, 622 (2021).","journal-title":"Biomolecules"},{"key":"2742_CR35","doi-asserted-by":"publisher","first-page":"18490","DOI":"10.1073\/pnas.0809242105","volume":"105","author":"RR Weichselbaum","year":"2008","unstructured":"Weichselbaum, R. R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 105, 18490\u201318495 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2742_CR36","doi-asserted-by":"publisher","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","volume":"6","author":"P Casado","year":"2013","unstructured":"Casado, P. et al. Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci. Signal 6, rs6 (2013).","journal-title":"Sci. Signal"},{"key":"2742_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14, 130\u2013146 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2742_CR38","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1158\/1078-0432.CCR-10-2578","volume":"17","author":"A Saha","year":"2011","unstructured":"Saha, A. & Robertson, E. S. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin. Cancer Res 17, 3056\u20133063 (2011).","journal-title":"Clin. Cancer Res"},{"key":"2742_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-025-00720-9","volume":"21","author":"Q Xiao","year":"2025","unstructured":"Xiao, Q. et al. Epstein-Barr virus infection shapes the genetic, transcriptomic, and immune microenvironment landscape of Burkitt lymphoma. Infect. Agent Cancer 21, 4 (2025).","journal-title":"Infect. Agent Cancer"},{"key":"2742_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2014.07.006","volume":"29","author":"M Lederer","year":"2014","unstructured":"Lederer, M., Bley, N., Schleifer, C. & H\u00fcttelmaier, S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 29, 3\u201312 (2014).","journal-title":"Semin Cancer Biol."},{"key":"2742_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrm3624","volume":"14","author":"DA Calderwood","year":"2013","unstructured":"Calderwood, D. A., Campbell, I. D. & Critchley, D. R. Talins and kindlins: Partners in integrin-mediated adhesion. Nat. Rev. Mol. Cell Biol. 14, 503\u2013517 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2742_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"2742_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J. & Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 21, 147\u2013164 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2742_CR44","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.trecan.2021.06.007","volume":"7","author":"S Gao","year":"2021","unstructured":"Gao, S., Hsu, T. W. & Li, M. O. Immunity beyond cancer cells: Perspective from tumor tissue. Trends Cancer 7, 1010\u20131019 (2021).","journal-title":"Trends Cancer"},{"key":"2742_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","volume":"24","author":"DC Mastellos","year":"2024","unstructured":"Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. A guide to complement biology, pathology and therapeutic opportunity. Nat. Rev. Immunol. 24, 118\u2013141 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2742_CR46","doi-asserted-by":"publisher","first-page":"215900","DOI":"10.1016\/j.canlet.2022.215900","volume":"549","author":"Y Senent","year":"2022","unstructured":"Senent, Y., Tavira, B., Pio, R. & Ajona, D. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells. Cancer Lett. 549, 215900 (2022).","journal-title":"Cancer Lett."},{"key":"2742_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.celrep.2019.05.111","volume":"28","author":"DJ Young","year":"2019","unstructured":"Young, D. J. & Guydosh, N. R. Hcr1\/eIF3j Is a 60S Ribosomal Subunit Recycling Accessory Factor In Vivo. Cell Rep. 28, 39\u201350.e34 (2019).","journal-title":"Cell Rep."},{"key":"2742_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2004.05.024","volume":"5","author":"S Avdulov","year":"2004","unstructured":"Avdulov, S. et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5, 553\u2013563 (2004).","journal-title":"Cancer Cell"},{"key":"2742_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41586-020-2842-3","volume":"587","author":"H Sedlackova","year":"2020","unstructured":"Sedlackova, H. et al. Equilibrium between nascent and parental MCM proteins protects replicating genomes. Nature 587, 297\u2013302 (2020).","journal-title":"Nature"},{"key":"2742_CR50","doi-asserted-by":"publisher","first-page":"713026","DOI":"10.3389\/fonc.2021.713026","volume":"11","author":"NE Topalov","year":"2021","unstructured":"Topalov, N. E. et al. Actin beta-like 2 as a new mediator of proliferation and migration in epithelial ovarian cancer. Front Oncol. 11, 713026 (2021).","journal-title":"Front Oncol."},{"key":"2742_CR51","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s43018-019-0021-y","volume":"1","author":"M Cong","year":"2020","unstructured":"Cong, M. et al. MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination. Nat. Cancer 1, 222\u2013234 (2020).","journal-title":"Nat. Cancer"},{"key":"2742_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05630-9","volume":"22","author":"VT Duong","year":"2024","unstructured":"Duong, V. T. et al. Recycling machinery of integrin coupled with focal adhesion turnover via RAB11-UNC13D-FAK axis for migration of pancreatic cancer cells. J. Transl. Med 22, 800 (2024).","journal-title":"J. Transl. Med"},{"key":"2742_CR53","first-page":"1437","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. a next generation connectivity map: L1000 platform and the first 1,000,000. Profiles Cell 171, 1437\u20131452.e1417 (2017).","journal-title":"Profiles Cell"},{"key":"2742_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/med.21320","volume":"35","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med Res Rev. 35, 63\u201384 (2015).","journal-title":"Med Res Rev."},{"key":"2742_CR55","doi-asserted-by":"crossref","unstructured":"Quaas, M. et al. BRCA1 and BRCA2 gene expression: p53- and cell cycle-dependent repression requires RB and DREAM. Cell Death Differ (2025).","DOI":"10.1038\/s41418-025-01566-9"},{"key":"2742_CR56","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/jpm11101009","volume":"11","author":"WJ Hsu","year":"2021","unstructured":"Hsu, W. J. et al. PRMT1 confers resistance to olaparib via modulating MYC signaling in triple-negative breast cancer. J. Pers. Med. 11, 1009 (2021).","journal-title":"J. Pers. Med"},{"key":"2742_CR57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang, R. X. & Zhou, P. K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target Ther. 5, 60 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2742_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48715-1","volume":"15","author":"D Dibitetto","year":"2024","unstructured":"Dibitetto, D. et al. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours. Nat. Commun. 15, 4430 (2024).","journal-title":"Nat. Commun."},{"key":"2742_CR59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.freeradbiomed.2010.11.011","volume":"50","author":"P Pettazzoni","year":"2011","unstructured":"Pettazzoni, P. et al. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic. Biol. Med. 50, 313\u2013322 (2011).","journal-title":"Free Radic. Biol. Med."},{"key":"2742_CR60","doi-asserted-by":"publisher","first-page":"26604","DOI":"10.18632\/oncotarget.8445","volume":"7","author":"MY Wang","year":"2016","unstructured":"Wang, M. Y. et al. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival. Oncotarget 7, 26604\u201326616 (2016).","journal-title":"Oncotarget"},{"key":"2742_CR61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-020-0151-9","volume":"5","author":"L Xie","year":"2020","unstructured":"Xie, L. et al. Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. Signal Transduct. Target Ther. 5, 56 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2742_CR62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41420-022-00844-6","volume":"8","author":"M Du","year":"2022","unstructured":"Du, M. et al. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma. Cell Death Discov. 8, 53 (2022).","journal-title":"Cell Death Discov."},{"key":"2742_CR63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/sj.bjc.6604167","volume":"98","author":"SJ Liu","year":"2008","unstructured":"Liu, S. J. et al. Downregulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma. Br. J. Cancer 98, 363\u2013369 (2008).","journal-title":"Br. J. Cancer"},{"key":"2742_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1354940","volume":"14","author":"Y Tan","year":"2024","unstructured":"Tan, Y. et al. Novel prognostic biomarkers in nasopharyngeal carcinoma unveiled by mega-data bioinformatics analysis. Front Oncol. 14, 1354940 (2024).","journal-title":"Front Oncol."},{"key":"2742_CR65","first-page":"916","volume":"18","author":"Z Zou","year":"2019","unstructured":"Zou, Z., Gan, S., Liu, S., Li, R. & Huang, J. Investigation of differentially expressed genes in nasopharyngeal carcinoma by integrated bioinformatics analysis. Oncol. Lett. 18, 916\u2013926 (2019).","journal-title":"Oncol. Lett."},{"key":"2742_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0568-5","volume":"16","author":"C Altenberger","year":"2017","unstructured":"Altenberger, C. et al. SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Mol. Cancer 16, 1 (2017).","journal-title":"Mol. Cancer"},{"key":"2742_CR67","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1182\/bloodadvances.2021006920","volume":"6","author":"J Mu","year":"2022","unstructured":"Mu, J. et al. Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression. Blood Adv. 6, 5379\u20135394 (2022).","journal-title":"Blood Adv."},{"key":"2742_CR68","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1111\/jcmm.13623","volume":"22","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. The role of septin 7 in physiology and pathological disease: A systematic review of current status. J. Cell Mol. Med 22, 3298\u20133307 (2018).","journal-title":"J. Cell Mol. Med"},{"key":"2742_CR69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3892\/ijo.2021.5205","volume":"58","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo\/YAP signaling pathway. Int J. Oncol. 58, 25 (2021).","journal-title":"Int J. Oncol."},{"key":"2742_CR70","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/0008-5472.CAN-17-2899","volume":"78","author":"AK Simi","year":"2018","unstructured":"Simi, A. K. et al. A soft microenvironment protects from failure of midbody abscission and multinucleation downstream of the EMT-promoting transcription factor snail. Cancer Res. 78, 2277\u20132289 (2018).","journal-title":"Cancer Res."},{"key":"2742_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/srep07546","volume":"4","author":"Y Wei","year":"2014","unstructured":"Wei, Y. et al. MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci. Rep. 4, 7546 (2014).","journal-title":"Sci. Rep."},{"key":"2742_CR72","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1001\/jama.2016.5989","volume":"315","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo, K. et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 315, 2564\u20132575 (2016).","journal-title":"JAMA"},{"key":"2742_CR73","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.biopha.2016.06.051","volume":"83","author":"E Drozd","year":"2016","unstructured":"Drozd, E. et al. Up-regulation of glutathione-related genes, enzyme activities and transport proteins in human cervical cancer cells treated with doxorubicin. Biomed. Pharmacother. 83, 397\u2013406 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"2742_CR74","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fcell.2018.00066","volume":"6","author":"Y Qi","year":"2018","unstructured":"Qi, Y. & Xu, R. Roles of PLODs in collagen synthesis and cancer progression. Front Cell Dev. Biol. 6, 66 (2018).","journal-title":"Front Cell Dev. Biol."},{"key":"2742_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110609","volume":"105","author":"R Zhou","year":"2023","unstructured":"Zhou, R. et al. P4HA1 activates HMGCS1 to promote nasopharyngeal carcinoma ferroptosis resistance and progression. Cell Signal 105, 110609 (2023).","journal-title":"Cell Signal"},{"key":"2742_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01502-2","volume":"21","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1\/c-Myc positive feedback loop. Mol. Cancer 21, 62 (2022).","journal-title":"Mol. Cancer"},{"key":"2742_CR77","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.7314\/APJCP.2012.13.12.6527","volume":"13","author":"JR He","year":"2012","unstructured":"He, J. R. et al. Complement receptor 1 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma. Asian Pac. J. Cancer Prev. 13, 6527\u20136531 (2012).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2742_CR78","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1128\/jvi.63.10.4121-4128.1989","volume":"63","author":"M Billaud","year":"1989","unstructured":"Billaud, M. et al. Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2\/CD23 and low levels of the EBV receptor CR2. J. Virol. 63, 4121\u20134128 (1989).","journal-title":"J. Virol."},{"key":"2742_CR79","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","volume":"19","author":"LT Roumenina","year":"2019","unstructured":"Roumenina, L. T., Daugan, M. V., Petitprez, F., Saut\u00e8s-Fridman, C. & Fridman, W. H. Context-dependent roles of complement in cancer. Nat. Rev. Cancer 19, 698\u2013715 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2742_CR80","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1172\/JCI129049","volume":"130","author":"TTT Nguyen","year":"2020","unstructured":"Nguyen, T. T. T. et al. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J. Clin. Invest 130, 3699\u20133716 (2020).","journal-title":"J. Clin. Invest"},{"key":"2742_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07767-w","volume":"9","author":"Q Jia","year":"2018","unstructured":"Jia, Q. et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat. Commun. 9, 5361 (2018).","journal-title":"Nat. Commun."},{"key":"2742_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0620-6","volume":"16","author":"M Angelova","year":"2015","unstructured":"Angelova, M. et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).","journal-title":"Genome Biol."},{"key":"2742_CR83","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nprot.2012.016","volume":"7","author":"C Trapnell","year":"2012","unstructured":"Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562\u2013578 (2012).","journal-title":"Nat. Protoc."},{"key":"2742_CR84","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211\u2013d1217 (2019).","journal-title":"Nucleic Acids Res"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02742-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:01:58Z","timestamp":1782169318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02742-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2742"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02742-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}